We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Events

09 Apr 2024 - 12 Apr 2024
15 Apr 2024 - 17 Apr 2024
23 Apr 2024 - 26 Apr 2024

High Levels of Blood Hormones Raise Prostate Cancer Risk

By LabMedica International staff writers
Posted on 11 Nov 2019
Print article
Image: Histopathology of prostate cancer: crystalloids (bright eosinophilic rhomboid to prismatic structures, seen in ~40% cancer) and amorphous eosinophilic secretions (Photo courtesy the American Urological Association).
Image: Histopathology of prostate cancer: crystalloids (bright eosinophilic rhomboid to prismatic structures, seen in ~40% cancer) and amorphous eosinophilic secretions (Photo courtesy the American Urological Association).
Men with higher levels of 'free' testosterone and a growth hormone in their blood are more likely to be diagnosed with prostate cancer. Other factors such as older age, ethnicity and a family history of the disease are already known to increase a man's risk of developing prostate cancer.

Prostate cancer is one of the most common types of cancer in men. Usually prostate cancer grows slowly and is initially confined to the prostate gland, where it may not cause serious harm. However, while some types of prostate cancer grow slowly and may need minimal or even no treatment, other types are aggressive and can spread quickly.

A team of scientists working with those at the University of Oxford (Oxford, UK) studied 200,452 men who are part of the UK Biobank project. All were free of cancer when they joined the study and were not taking any hormone therapy. The men gave blood samples that were tested for their levels of testosterone and a growth hormone called insulin-like growth factor-I (IGF-I). The team calculated levels of free testosterone, which is testosterone that is circulating in the blood and not bound to any other molecule and can therefore have an effect in the body. A subset of 9,000 of men gave a second blood sample at a later date, to help the investigators account for natural fluctuations in hormone levels. The men were followed for an average of six to seven years to see if they went on to develop prostate cancer. Within the group, there were 5,412 cases and 296 deaths from the disease.

The scientists reported that men with higher concentrations of the two hormones in their blood were more likely to be diagnosed with prostate cancer. For every increase 5 nmol/L of IGF-I, men were 9% more likely to develop prostate cancer. For every increase of 50 pmol/L, there was a 10% increase in prostate cancer risk. Looking at the population as a whole, the scientists say their findings correspond to a 25% greater risk in men who have the highest levels of IGF-I, compared to those with the lowest. Men with the highest 'free' testosterone levels face a 18% greater risk of prostate cancer, compared to those with the lowest levels.

Hashim Ahmed, MD, a Professor Urology at Imperial College London (London, UK), said, “These results are important because they show that there are at least some factors that influence prostate cancer risk that can potentially be altered. In the longer term, it could mean that we can give men better advice on how to take steps to reduce their own risk. This study also shows the importance of carrying out very large studies, which are only possible thanks to the thousands of men who agreed to take part.” The study was presented at the National Cancer Research Institute 2019 cancer conference held November 3 – November 5, 2019 in Glasgow, UK.

Related Links:
University of Oxford
Imperial College London


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Specimen Collection & Transport
Complement 3 (C3) Test
GPP-100 C3 Kit
New
Gold Member
Systemic Autoimmune Testing Assay
BioPlex 2200 ANA Screen with MDSS

Print article

Channels

Molecular Diagnostics

view channel
Image: MOF materials efficiently enrich cfDNA and cfRNA in blood through simple operational process (Photo courtesy of Science China Press)

Blood Circulating Nucleic Acid Enrichment Technique Enables Non-Invasive Liver Cancer Diagnosis

The ability to diagnose diseases early can significantly enhance the effectiveness of clinical treatments and improve survival rates. One promising approach for non-invasive early diagnosis is the use... Read more

Hematology

view channel
Image: The low-cost portable device rapidly identifies chemotherapy patients at risk of sepsis (Photo courtesy of 52North Health)

POC Finger-Prick Blood Test Determines Risk of Neutropenic Sepsis in Patients Undergoing Chemotherapy

Neutropenia, a decrease in neutrophils (a type of white blood cell crucial for fighting infections), is a frequent side effect of certain cancer treatments. This condition elevates the risk of infections,... Read more

Pathology

view channel
Image: The OvaCis Rapid Test discriminates benign from malignant epithelial ovarian cysts (Photo courtesy of INEX)

Intra-Operative POC Device Distinguishes Between Benign and Malignant Ovarian Cysts within 15 Minutes

Ovarian cysts represent a significant health issue for women globally, with up to 10% experiencing this condition at some point in their lives. These cysts form when fluid collects within a thin membrane... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.